DE69114614T2 - Polyethylenglykolderivate, modifizierte Peptide derselben, ihre Herstellung sowie Verwendung der modifizierten Peptide. - Google Patents
Polyethylenglykolderivate, modifizierte Peptide derselben, ihre Herstellung sowie Verwendung der modifizierten Peptide.Info
- Publication number
- DE69114614T2 DE69114614T2 DE69114614T DE69114614T DE69114614T2 DE 69114614 T2 DE69114614 T2 DE 69114614T2 DE 69114614 T DE69114614 T DE 69114614T DE 69114614 T DE69114614 T DE 69114614T DE 69114614 T2 DE69114614 T2 DE 69114614T2
- Authority
- DE
- Germany
- Prior art keywords
- polyethylene glycol
- modified peptides
- glycol derivatives
- peptides
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
- C08G65/3326—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
- C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
- C08G65/3315—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic aromatic
- C08G65/3317—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic aromatic phenolic
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyethers (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2227541A JP3051145B2 (ja) | 1990-08-28 | 1990-08-28 | 新規なポリエチレングリコール誘導体修飾ペプチド |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69114614D1 DE69114614D1 (de) | 1995-12-21 |
DE69114614T2 true DE69114614T2 (de) | 1996-03-28 |
Family
ID=16862521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69114614T Expired - Fee Related DE69114614T2 (de) | 1990-08-28 | 1991-08-24 | Polyethylenglykolderivate, modifizierte Peptide derselben, ihre Herstellung sowie Verwendung der modifizierten Peptide. |
Country Status (9)
Country | Link |
---|---|
US (1) | US5183660A (de) |
EP (1) | EP0473084B1 (de) |
JP (1) | JP3051145B2 (de) |
AT (1) | ATE130327T1 (de) |
CA (1) | CA2050063A1 (de) |
DE (1) | DE69114614T2 (de) |
DK (1) | DK0473084T3 (de) |
ES (1) | ES2079534T3 (de) |
GR (1) | GR3018612T3 (de) |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5951972A (en) * | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
WO1993012145A1 (en) * | 1991-12-19 | 1993-06-24 | Baylor College Of Medicine | Pva or peg conjugates of peptides for epitope-specific immunosuppression |
US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
MD1486G2 (ro) * | 1992-10-29 | 2001-11-30 | Genentech, Inc. | Metodă de tratament sau profilaxie a obezităţii |
US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US6015897A (en) * | 1993-12-07 | 2000-01-18 | Neorx Corporation | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota |
US5550212A (en) * | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
US5441544A (en) * | 1993-12-23 | 1995-08-15 | Chevron Chemical Company | Fuel compositions containing substituted poly(oxyalkylene) aromatic ethers |
US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
JP3708151B2 (ja) * | 1994-12-15 | 2005-10-19 | 協和醗酵工業株式会社 | Peg化したヒト顆粒球コロニー刺激因子の定量法 |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
DE69631329T2 (de) * | 1995-03-10 | 2004-11-18 | Sumitomo Pharmaceuticals Co., Ltd. | Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol |
DE19514087A1 (de) * | 1995-04-13 | 1996-10-17 | Deutsches Krebsforsch | Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein |
US5756593A (en) * | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
EP0922446A1 (de) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Lösungsphase Verfahrung zur ortspezifischer Herstellung von GRF-PEG Konjugaten |
US6066673A (en) * | 1998-03-12 | 2000-05-23 | The Procter & Gamble Company | Enzyme inhibitors |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6251382B1 (en) | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
WO2001048052A1 (fr) * | 1999-12-24 | 2001-07-05 | Kyowa Hakko Kogyo Co., Ltd. | Glycols de polyalkylene ramifies |
MXPA03007392A (es) * | 2001-02-20 | 2003-12-04 | Enzon Inc | Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos. |
AR033903A1 (es) * | 2001-05-21 | 2004-01-07 | Inhale Therapeutic Syst | Una composicion de insulina modificada quimicamente para la administracion pulmonar |
DE60223047T2 (de) | 2001-08-22 | 2008-07-24 | Bioartificial Gel Technologies Inc., Montreal | Verfahren zur herstellung von aktivierten polyethylenglykolen |
US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
TWI281864B (en) * | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
RS20050502A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of interferon- beta with enhanced biological potency |
NZ541122A (en) * | 2002-12-26 | 2008-09-26 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
JP4369194B2 (ja) * | 2003-09-30 | 2009-11-18 | Hoya株式会社 | プラスチックレンズ及びその製造方法 |
KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
NZ586034A (en) * | 2004-02-02 | 2011-10-28 | Ambrx Inc | Modified human growth hormone polypeptides and their uses |
US7351787B2 (en) * | 2004-03-05 | 2008-04-01 | Bioartificial Gel Technologies, Inc. | Process for the preparation of activated polyethylene glycols |
WO2005107815A2 (en) * | 2004-05-03 | 2005-11-17 | Nektar Therapeutics Al, Corporation | Polymer derivatives comprising an imide branching point |
WO2006034455A2 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
EP1674113A1 (de) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol) |
BRPI0519430A2 (pt) | 2004-12-22 | 2009-02-10 | Ambrx Inc | hormânio do crescimento humano modificado |
SG161209A1 (en) * | 2004-12-22 | 2010-05-27 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
KR20070100299A (ko) | 2004-12-22 | 2007-10-10 | 암브룩스, 인코포레이티드 | 재조합 인간 성장 호르몬의 발현 및 정제 방법 |
AU2006203792B2 (en) | 2005-01-10 | 2011-11-03 | Ratiopharm Gmbh | Glycopegylated Granulocyte Colony Stimulating Factor |
DE602005015817D1 (de) * | 2005-01-25 | 2009-09-17 | Varian B V | Chromatographische Säulen |
EP1871795A4 (de) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
EP1891231A4 (de) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | Glykopegylierter faktor ix |
BRPI0611872B8 (pt) | 2005-06-16 | 2021-05-25 | Nektar Therapeutics | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
US7989554B2 (en) * | 2006-01-10 | 2011-08-02 | Enzon Pharmaceuticals, Inc. | Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
KR101106795B1 (ko) | 2006-08-31 | 2012-01-18 | 에프. 호프만-라 로슈 아게 | 인슐린-유사 성장 인자-i의 제조 방법 |
LT2068907T (lt) | 2006-10-04 | 2018-01-10 | Novo Nordisk A/S | Glicerolio sujungti pegilinti sacharidai ir glikopeptidai |
US8043829B2 (en) | 2006-10-25 | 2011-10-25 | Amgen Inc. | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression |
EP2121743B1 (de) | 2006-11-22 | 2015-06-03 | Bristol-Myers Squibb Company | Gezielte therapeutika auf der basis von manipulierten proteinen für tyrosinkinaserezeptoren, einschliesslich igf-ir |
CA2677253C (en) * | 2007-02-01 | 2015-06-30 | National Research Council Of Canada | Formulations of lipophilic bioactive molecules |
WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
EP2738257A1 (de) | 2007-05-22 | 2014-06-04 | Amgen Inc. | Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine |
CL2008002054A1 (es) * | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
AR067537A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Purificacion de polipeptidos pegilados |
CN102099373A (zh) | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
US8067201B2 (en) | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
ES2966234T3 (es) | 2009-06-09 | 2024-04-18 | Prolong Pharmaceuticals Llc | Composiciones de hemoglobina |
MX339559B (es) | 2010-02-11 | 2016-05-31 | Hoffmann La Roche | Conjugados de igf-i poli(etilenglicol). |
EP3091028A1 (de) | 2010-05-26 | 2016-11-09 | Bristol-Myers Squibb Company | Auf fibronectin basierende gerüstproteine mit erhöhter stabilität |
PL2616101T3 (pl) | 2010-09-14 | 2015-01-30 | Hoffmann La Roche | Sposób oczyszczania pegylowanej erytropoetyny |
SG10201601789TA (en) | 2011-03-16 | 2016-04-28 | Amgen Inc | Potent And Selective Inhibitors Of Nav1.3 And Nav1.7 |
WO2012158678A1 (en) | 2011-05-17 | 2012-11-22 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
WO2013138338A2 (en) | 2012-03-12 | 2013-09-19 | Massachusetts Institute Of Technology | Methods for treating tissue damage associated with ischemia with apoliporotein d |
EP2830663B1 (de) | 2012-03-30 | 2019-02-06 | Sorrento Therapeutics Inc. | Vollständig humane, an vegfr2 bindende antikörper |
WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
JP6429771B2 (ja) | 2012-06-21 | 2018-11-28 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | c−Metに結合する抗原結合タンパク質 |
CA2877814A1 (en) | 2012-06-22 | 2013-12-27 | Dingqiu HUANG | Antigen binding proteins that bind ccr2 |
KR102187714B1 (ko) | 2012-09-13 | 2020-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질 |
WO2014099984A1 (en) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
CA2951391C (en) | 2014-06-10 | 2021-11-02 | Amgen Inc. | Apelin polypeptides |
US10166273B2 (en) | 2014-08-12 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein |
US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
EA201790437A1 (ru) | 2014-08-22 | 2017-08-31 | Сорренто Терапьютикс, Инк. | Антигенсвязывающие белки, связывающиеся с cxcr3 |
EP3224277B1 (de) | 2014-11-25 | 2020-08-26 | Bristol-Myers Squibb Company | Neuartige pd-l1-bindende polypeptide zur bildgebung |
BR112017010414A2 (pt) | 2014-11-25 | 2018-05-15 | Bristol-Myers Squibb Company | métodos e composições para radiomarcação com 18f de substâncias biológicas |
WO2016130986A1 (en) | 2015-02-13 | 2016-08-18 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
AR104213A1 (es) | 2015-04-08 | 2017-07-05 | Sorrento Therapeutics Inc | Anticuerpos anti-cd38 como agentes terapéuticos |
ES2884267T3 (es) | 2015-04-24 | 2021-12-10 | Viiv Healthcare Uk No 5 Ltd | Polipéptidos dirigidos a la fusión con el vih |
CN108884147B (zh) | 2015-09-23 | 2024-02-27 | 百时美施贵宝公司 | 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子 |
AU2017212717B2 (en) | 2016-01-29 | 2023-11-16 | Yuhan Corporation | Antigen binding proteins that bind PD-L1 |
US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
KR20220158870A (ko) | 2016-07-15 | 2022-12-01 | 에프. 호프만-라 로슈 아게 | Peg화 에리트로포이에틴을 정제하기 위한 방법 |
WO2019036605A2 (en) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF |
JP7227633B2 (ja) | 2017-12-29 | 2023-02-22 | エフ. ホフマン-ラ ロシュ エージー. | Peg化タンパク質組成物を提供するための方法 |
US20200323993A1 (en) | 2017-12-29 | 2020-10-15 | Hoffmann-La Roche Inc. | Process for providing pegylated protein composition |
CN111801120A (zh) | 2017-12-29 | 2020-10-20 | 豪夫迈·罗氏有限公司 | 用于提供聚乙二醇化蛋白质组合物的方法 |
BR112021004383A2 (pt) | 2018-09-28 | 2021-08-03 | Massachusetts Institute Of Technology | proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito |
WO2020154032A1 (en) | 2019-01-23 | 2020-07-30 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
US20210221886A1 (en) | 2019-12-05 | 2021-07-22 | Sorrento Therapeutics, Inc. | Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody |
US20210188934A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
CN115485300A (zh) | 2020-02-26 | 2022-12-16 | 索伦托药业有限公司 | 具有通用掩蔽部分的可活化的抗原结合蛋白 |
WO2021174045A1 (en) | 2020-02-28 | 2021-09-02 | Bristol-Myers Squibb Company | Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof |
WO2021195089A1 (en) | 2020-03-23 | 2021-09-30 | Sorrento Therapeutics, Inc. | Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof |
BR112022022899A2 (pt) | 2020-05-12 | 2022-12-20 | Regeneron Pharma | Agonistas de il10 e métodos de uso dos mesmos |
US11241410B2 (en) * | 2020-05-18 | 2022-02-08 | Amanuel Tesfazion | Method and compound for the treatment of covid-19 |
CN116209677A (zh) | 2020-06-26 | 2023-06-02 | 索伦托药业有限公司 | 抗pd1抗体及其用途 |
TW202322846A (zh) | 2021-08-16 | 2023-06-16 | 美商再生元醫藥公司 | 新穎的il27受體促效劑及其使用方法 |
WO2023086812A1 (en) | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE32439B1 (en) * | 1967-09-27 | 1973-08-08 | Madan Ag | Substituted phenylacetic acids and process of preparation thereof |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
EP0011279B1 (de) * | 1978-11-14 | 1982-05-05 | Sagami Chemical Research Center | Verfahren zur Herstellung aromatisch substituierter Essigsäuren |
DE3125059A1 (de) * | 1981-06-26 | 1983-01-05 | Bayer Ag, 5090 Leverkusen | Dioxybenzoletherderivate, diese enthaltende arzneimittel, verfahren zu ihrer herstellung und ihre verwendung |
DE3572982D1 (en) * | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
JPS6142558A (ja) * | 1984-08-06 | 1986-03-01 | Matsushita Electric Works Ltd | アミノ樹脂成形材料 |
ES8800982A1 (es) * | 1985-07-05 | 1987-12-01 | Takeda Chemical Industries Ltd | Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina. |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
JPS63146791A (ja) * | 1986-12-08 | 1988-06-18 | Hitachi Ltd | 酵素の固定化方法 |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
IT1216473B (it) * | 1988-02-29 | 1990-03-08 | Montefibre Spa | Derivati poliossialchilen_etere_terminati di acidi organici, loro esteri alchilici e loro sali alcalini e alcalino terrosi. |
CA1340810C (en) * | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
JP2958019B2 (ja) * | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
JP2997004B2 (ja) * | 1989-05-26 | 2000-01-11 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
-
1990
- 1990-08-28 JP JP2227541A patent/JP3051145B2/ja not_active Expired - Lifetime
-
1991
- 1991-08-15 US US07/745,496 patent/US5183660A/en not_active Expired - Fee Related
- 1991-08-24 ES ES91114221T patent/ES2079534T3/es not_active Expired - Lifetime
- 1991-08-24 AT AT91114221T patent/ATE130327T1/de not_active IP Right Cessation
- 1991-08-24 DK DK91114221.4T patent/DK0473084T3/da active
- 1991-08-24 EP EP91114221A patent/EP0473084B1/de not_active Expired - Lifetime
- 1991-08-24 DE DE69114614T patent/DE69114614T2/de not_active Expired - Fee Related
- 1991-08-27 CA CA002050063A patent/CA2050063A1/en not_active Abandoned
-
1996
- 1996-01-09 GR GR960400028T patent/GR3018612T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0473084B1 (de) | 1995-11-15 |
DE69114614D1 (de) | 1995-12-21 |
JPH04108827A (ja) | 1992-04-09 |
JP3051145B2 (ja) | 2000-06-12 |
CA2050063A1 (en) | 1992-03-01 |
DK0473084T3 (da) | 1996-03-04 |
EP0473084A3 (en) | 1992-04-29 |
ATE130327T1 (de) | 1995-12-15 |
ES2079534T3 (es) | 1996-01-16 |
GR3018612T3 (en) | 1996-04-30 |
EP0473084A2 (de) | 1992-03-04 |
US5183660A (en) | 1993-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69114614T2 (de) | Polyethylenglykolderivate, modifizierte Peptide derselben, ihre Herstellung sowie Verwendung der modifizierten Peptide. | |
EP0340741A3 (de) | Polyäthylenglykolderivate, modifizierte Peptide und ihre Herstellung | |
EA200400432A1 (ru) | Производные мочевины | |
DE59002783D1 (de) | Diphenylheteroalkylderivate, ihre Herstellung und daraus hergestellte Arzneimittel und Kosmetika. | |
DE3883016D1 (de) | Komplexe verbindungen aus bioflavonoiden mit phospholipiden, ihre herstellung und verwendung und sie enthaltende pharmazeutische und kosmetische zusammensetzungen. | |
DE59009351D1 (de) | Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel. | |
DE69112989T2 (de) | Aminocoumaranderivate, ihre Herstellung und Verwendung. | |
DE69010139T2 (de) | Haarkräftigungsmittel. | |
DE69114117T2 (de) | Neue Verwendung von Peptidderivat. | |
ATE179706T1 (de) | N-heteroaryl-n'-phenylharnstoffderivate, ihre herstellung und verwendung | |
DE69627035T2 (de) | Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren | |
FI920023A0 (fi) | Heteroarylpiperazinfoereningar som antipsykotiska aemnen. | |
DE68906609D1 (de) | Dopamin-vorlaeufer. | |
DE59001281D1 (de) | Oxidierte diphenylheteroalkane, ihre herstellung und verwendung. | |
EP0400486A3 (de) | Polyethylenglycolderivate, modifizierte Peptide und ihre Herstellung | |
DE58905079D1 (de) | Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung. | |
DE59203924D1 (de) | Substituierte Aminosäureamid-Derivate deren Herstellung und Verwendung als Fungizide. | |
DE69224613T2 (de) | Peptide, Herstellung und deren Verwendung | |
DE68906572T2 (de) | Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
ATE171704T1 (de) | Optisch wirksame alkylendioxybenzolderivate und ihre verwendung als arzneimittel | |
DE69111401D1 (de) | Tert-Butyloxycarbonyl-L-Tyrosyl-Peptidoglycanmonomer und deren 125 I-markiertes Derivat, deren Herstellung und Verwendung. | |
DE59003446D1 (de) | 13-Brom und 13, 14-Dibrom-Ergoline, ihre Herstellung und Verwendung in Arzneimitteln. | |
ATE186214T1 (de) | Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen | |
DE69511449T2 (de) | Octahydro-2-Naphthalincarbonsäure-Derivate, ihre Herstellung und Verwendung | |
DE3781044D1 (de) | Prophylaktische und heilende zusammensetzung enthaltende eine 8-chlorbenzothiazepin-verbindung und dessen verwendung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |